This award recognises a European company that has successfully completed a significant or transformational IPO in the period between 1 September 2017 and 1 September 2018.
Judges paid particular attention to:
Polyphor was founded in 1996 and is a clinical stage biopharmaceutical company based in Allschwil, Switzerland, near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and improve therapy outcomes in cancer.
A precision Outer Membrane Protein Targeting Antibiotic (OMPTA) against Pseudomonas aeruginosa
An antagonist of the chemokine receptor CXCR4 for combination treatment in oncology
POL6014 – Outlicensed to Santhera on 14.02.2018
An inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases